ICU Medical (NASDAQ:ICUI) Raised to Buy at StockNews.com

StockNews.com upgraded shares of ICU Medical (NASDAQ:ICUI) from a hold rating to a buy rating in a report released on Wednesday morning.

Other research analysts have also recently issued research reports about the company. Needham & Company LLC reaffirmed a “hold” rating on shares of ICU Medical in a research report on Wednesday, November 13th. Jefferies Financial Group assumed coverage on shares of ICU Medical in a report on Monday, October 14th. They set a “hold” rating and a $183.00 price objective on the stock. KeyCorp increased their target price on shares of ICU Medical from $198.00 to $209.00 and gave the company an “overweight” rating in a report on Wednesday, November 13th. Finally, Raymond James boosted their price target on shares of ICU Medical from $158.00 to $190.00 and gave the stock an “outperform” rating in a report on Thursday, September 12th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $173.00.

ICU Medical Trading Down 0.2 %

ICUI opened at $168.46 on Wednesday. The firm has a market capitalization of $4.12 billion, a PE ratio of -36.86 and a beta of 0.66. The company has a debt-to-equity ratio of 0.75, a current ratio of 2.29 and a quick ratio of 1.03. ICU Medical has a fifty-two week low of $83.26 and a fifty-two week high of $196.26. The company’s 50-day moving average is $176.22 and its 200 day moving average is $145.40.

Insider Activity at ICU Medical

In other ICU Medical news, CEO Vivek Jain sold 12,000 shares of the stock in a transaction on Friday, November 1st. The stock was sold at an average price of $171.84, for a total transaction of $2,062,080.00. Following the completion of the transaction, the chief executive officer now directly owns 104,593 shares of the company’s stock, valued at approximately $17,973,261.12. This represents a 10.29 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Daniel Woolson sold 2,502 shares of the firm’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $163.22, for a total value of $408,376.44. Following the completion of the sale, the vice president now directly owns 13,107 shares of the company’s stock, valued at $2,139,324.54. This represents a 16.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 38,502 shares of company stock worth $6,573,496. 6.70% of the stock is owned by company insiders.

Institutional Investors Weigh In On ICU Medical

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Innealta Capital LLC purchased a new position in shares of ICU Medical in the second quarter worth about $32,000. Hexagon Capital Partners LLC raised its holdings in ICU Medical by 162.7% during the 3rd quarter. Hexagon Capital Partners LLC now owns 197 shares of the medical instruments supplier’s stock valued at $36,000 after acquiring an additional 122 shares during the period. Allworth Financial LP boosted its holdings in shares of ICU Medical by 100.0% in the third quarter. Allworth Financial LP now owns 200 shares of the medical instruments supplier’s stock worth $36,000 after acquiring an additional 100 shares during the period. EntryPoint Capital LLC grew its position in shares of ICU Medical by 731.5% in the first quarter. EntryPoint Capital LLC now owns 449 shares of the medical instruments supplier’s stock valued at $48,000 after purchasing an additional 395 shares in the last quarter. Finally, Russell Investments Group Ltd. raised its stake in shares of ICU Medical by 46.4% during the 1st quarter. Russell Investments Group Ltd. now owns 546 shares of the medical instruments supplier’s stock valued at $59,000 after purchasing an additional 173 shares during the period. 96.10% of the stock is currently owned by institutional investors.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.